Meiqi Shi

Nanjing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Journal: JAMA

Published: June 17, 2026

Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy.

Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy.

Journal: Cancer biology & medicine

Published: December 10, 2025

Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.

Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 09, 2025

Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM).

Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM).

Journal: Nature communications

Published: August 29, 2025

Intracranial Efficacy of Crizotinib and Postprogression Therapeutic Strategies in Advanced c-ros Oncogene 1 (ROS1)-Positive Non-Small Cell Lung Cancer (NSCLC), a Multicenter Real-World Study.

Intracranial Efficacy of Crizotinib and Postprogression Therapeutic Strategies in Advanced c-ros Oncogene 1 (ROS1)-Positive Non-Small Cell Lung Cancer (NSCLC), a Multicenter Real-World Study.

Journal: MedComm

Published: July 30, 2025

Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer.

Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer.

Journal: Translational lung cancer research

Published: June 03, 2025

A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).

A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).

Journal: Future oncology (London, England)

Published: December 04, 2024

First-line serplulimab-based immunochemotherapy in elderly patients with extensive-stage small cell lung cancer: a multicenter, real-world study.

First-line serplulimab-based immunochemotherapy in elderly patients with extensive-stage small cell lung cancer: a multicenter, real-world study.

Journal: Journal of thoracic disease

Published: October 25, 2024

Induction Immunochemotherapy Followed by Hypo-Fractionated Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.

Induction Immunochemotherapy Followed by Hypo-Fractionated Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.

Journal: Clinical lung cancer

Published: October 21, 2024

Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.

Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.

Journal: Signal transduction and targeted therapy

Published: August 25, 2024

Integration of multiple machine learning approaches develops a gene mutation-based classifier for accurate immunotherapy outcomes.

Integration of multiple machine learning approaches develops a gene mutation-based classifier for accurate immunotherapy outcomes.

Journal: NPJ precision oncology

Published: July 11, 2024

Efficacy of disitamab vedotin in non-small cell lung cancer with HER2 alterations: a multicenter, retrospective real-world study.

Efficacy of disitamab vedotin in non-small cell lung cancer with HER2 alterations: a multicenter, retrospective real-world study.

Journal: Frontiers in oncology

Published: May 30, 2024

Showing 1-12 of 55

Last Updated: 09/26/2026